
MYOMO INC
MYONYSE AMERICANTrading Snapshot
- Day Range
- $1.50 โ $1.53
- 52-Week Range
- $0.61 โ $1.59
- Volume
- $4.20B
- Avg Volume
- $4.46B
- Shares Outstanding
- 38.6M
- Next Earnings
- Sep 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $41M
- Last Q Revenue
- $12M
- P/E Ratio
- -4.5
- P/S Ratio
- 1.4x
- EPS (TTM)
- $-0.34
- Dividend Yield
- 0.00%
Why Investors Own MYO
- โHigh-growth profile โ revenue up +55.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 27% gross margin and 6% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About MYOMO INC
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock rose
Myomo (NYSEARCA:MYO) Beats Q2 Estimates and Raises Full-Year Revenue Guidance
Myomo beats Q2 revenue and EPS estimates, raises full-year guidance, and shares jump 8.5% in after-hours trading.

Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript
Myomo, Inc. (MYO) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsPaul Gudonis - President, CEO & ChairmanDavid Henry - Chief...

Wondering what's happening in today's after-hours session?
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences (NASDAQ:CAI)
Myomo Sees Q3 Sales $11.500M-$12.000M vs $11.168M Est
Myomo (AMEX:MYO) sees Q3 sales of $11.500 million-$12.000 million vs $11.168 million analyst estimate.